SG10201805896SA - PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS - Google Patents
PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSISInfo
- Publication number
- SG10201805896SA SG10201805896SA SG10201805896SA SG10201805896SA SG10201805896SA SG 10201805896S A SG10201805896S A SG 10201805896SA SG 10201805896S A SG10201805896S A SG 10201805896SA SG 10201805896S A SG10201805896S A SG 10201805896SA SG 10201805896S A SG10201805896S A SG 10201805896SA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- multiple sclerosis
- pparγ agonists
- pparγ
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
Abstract
P P A R γ A G O N I S T S F O R T R E A T M E N T O F M U L T I P L E S C L E R O S I S M e t h o d s o f t r e a t m e n t o f m u l t i p l e s c l e r o s i s ( M S ) w i t h P P A R γ a g o n i s t s , a n d i n p a r t i c u l a r w i t h t h e compound of formula (I) known as INT131. Fig. 3
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758641P | 2013-01-30 | 2013-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201805896SA true SG10201805896SA (en) | 2018-08-30 |
Family
ID=51223587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505944QA SG11201505944QA (en) | 2013-01-30 | 2014-01-23 | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
| SG10201805896SA SG10201805896SA (en) | 2013-01-30 | 2014-01-23 | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505944QA SG11201505944QA (en) | 2013-01-30 | 2014-01-23 | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9061020B2 (en) |
| EP (1) | EP2950798B1 (en) |
| JP (3) | JP5989921B2 (en) |
| KR (2) | KR20150133182A (en) |
| CN (1) | CN105228622B (en) |
| AU (1) | AU2014212740B2 (en) |
| BR (1) | BR112015018048A2 (en) |
| CA (1) | CA2899187C (en) |
| EA (2) | EA029216B1 (en) |
| ES (1) | ES2883141T3 (en) |
| HK (1) | HK1218510A1 (en) |
| IL (2) | IL240051A (en) |
| MX (1) | MX366765B (en) |
| SG (2) | SG11201505944QA (en) |
| WO (1) | WO2014120538A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| KR20150133182A (en) * | 2013-01-30 | 2015-11-27 | 인테크린 테라퓨틱스, 아이엔씨. | Pparγ agonists for treatment of multiple sclerosis |
| SG10202103552XA (en) | 2015-03-09 | 2021-05-28 | Intekrin Therapeutics Inc | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| SG10202101500WA (en) * | 2016-08-18 | 2021-03-30 | Intekrin Therapeutics Inc | PPARγ AGONIST FOR TREATMENT OF BONE DISORDERS |
| EA201990512A1 (en) * | 2016-08-18 | 2019-08-30 | Интекрин Терапьютикс, Инк. | PPARγ AGONIST FOR TREATMENT OF MALIGNANT TUMORS OF BLOOD CELLS |
| US20190224186A1 (en) * | 2016-09-13 | 2019-07-25 | Intekrin Therapeutics, Inc. | Treatment of multiple sclerosis with chs-131 |
| CN110996951A (en) * | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | PPAR gamma agonists for the treatment of progressive supranuclear palsy |
| EA201992364A1 (en) * | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | PPARγ AGONIST FOR TREATMENT OF PROGRESSING NUCLEAR PARALYSIS |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050250820A1 (en) * | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| EP2175845A2 (en) * | 2007-07-11 | 2010-04-21 | Cardoz AB | New combination for use in the treatment of inflammatory disorders |
| WO2009097997A1 (en) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Substituted imidazolidine-2,4-diones, method for the production thereof, medicaments containing said compounds and use thereof |
| WO2010040055A2 (en) | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| US9675603B2 (en) * | 2010-09-21 | 2017-06-13 | Intekrin Therapeutics, Inc. | Solid pharmaceutical compositions of ppary modulator |
| KR20150133182A (en) * | 2013-01-30 | 2015-11-27 | 인테크린 테라퓨틱스, 아이엔씨. | Pparγ agonists for treatment of multiple sclerosis |
-
2014
- 2014-01-23 KR KR1020157023209A patent/KR20150133182A/en active Application Filing
- 2014-01-23 CN CN201480006782.8A patent/CN105228622B/en active Active
- 2014-01-23 ES ES14746632T patent/ES2883141T3/en active Active
- 2014-01-23 CA CA2899187A patent/CA2899187C/en active Active
- 2014-01-23 EP EP14746632.0A patent/EP2950798B1/en active Active
- 2014-01-23 BR BR112015018048A patent/BR112015018048A2/en not_active Application Discontinuation
- 2014-01-23 SG SG11201505944QA patent/SG11201505944QA/en unknown
- 2014-01-23 US US14/162,723 patent/US9061020B2/en active Active
- 2014-01-23 SG SG10201805896SA patent/SG10201805896SA/en unknown
- 2014-01-23 KR KR1020167032282A patent/KR102056756B1/en active IP Right Grant
- 2014-01-23 EA EA201591399A patent/EA029216B1/en unknown
- 2014-01-23 JP JP2015556062A patent/JP5989921B2/en active Active
- 2014-01-23 AU AU2014212740A patent/AU2014212740B2/en active Active
- 2014-01-23 EA EA201792096A patent/EA201792096A3/en unknown
- 2014-01-23 WO PCT/US2014/012656 patent/WO2014120538A1/en active Application Filing
- 2014-01-23 MX MX2015009818A patent/MX366765B/en active IP Right Grant
-
2015
- 2015-05-08 US US14/707,122 patent/US9539249B2/en active Active
- 2015-07-21 IL IL240051A patent/IL240051A/en active IP Right Grant
-
2016
- 2016-06-07 HK HK16106520.8A patent/HK1218510A1/en unknown
- 2016-08-09 JP JP2016156171A patent/JP6224189B2/en active Active
- 2016-10-30 IL IL248594A patent/IL248594B/en unknown
-
2017
- 2017-01-10 US US15/402,941 patent/US9867816B2/en active Active
- 2017-10-03 JP JP2017193213A patent/JP6466540B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| PH12016501192B1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| TN2018000020A1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors. | |
| MX2017002214A (en) | Process for the preparation of 5-fluoro-1h-pyrazoles starting from hexafluoropropene. | |
| NZ711192A (en) | Process for making benzoxazepin compounds | |
| MX2020003020A (en) | Aminocarbonylcarbamate compounds. | |
| AU2015339087B2 (en) | Trifluoromethyl alcohols as modulators of RORyt | |
| MX366983B (en) | 1,5-naphthyridine derivatives and melk inhibitors containing the same. | |
| MX2016015543A (en) | Process for the preparation of 5-fluoro-1h-pyrazoles starting from hexafluoropropene. | |
| MX2015016332A (en) | Pyrrolotriazines as alk inhibitors. | |
| EA201790687A1 (en) | QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | |
| EA201691999A1 (en) | NEW SULPHONYLAMINOBENZAMIDE COMPOUNDS | |
| MX2016006977A (en) | Process for the preparation of 5-fluoro-1(86) za 20150h-pyrazoles. | |
| CY1121116T1 (en) | NEW METHOD FOR THE COMPOSITION OF AGOMELATIN | |
| PH12016501183A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| WO2014177978A3 (en) | An improved process for the preparation of teriflunomide | |
| MX2018003903A (en) | Bicyclic compound and use thereof for inhibiting suv39h2. | |
| PH12016501182A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| PH12017500492A1 (en) | Crystalline bace inhibitors | |
| UA107468U (en) | 25,27-DI- (5-THIO-OCTYLOXES) CALIX [4] AREN-CROWN-6 | |
| UA91886U (en) | 1-tert-butoxy-3-(2,2,6,6-tetramethyl-4-hydroxypiperidino)-2-propanol | |
| MX2018011117A (en) | Crystalline form. | |
| UA90817U (en) | Compound 1,1-diethylcarboxy-2-trifluoromethyl-2-(5'-bromouridyl-1')ethylene with potential physiological properties |